Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sugammadex versus neostigmine for prevention of postoperative respiratory adverse events in older patients undergoing lung resection
ChiCTR2400094005Phase 4Completed
- Sponsor
- Shanghai Pulmonary Hospital
- Start
- Oct 2024
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 4 trial of Sugammadex, neostigmine and rocuronium in bronchial carcinoma (2 arms), sponsored by Shanghai Pulmonary Hospital. Primary endpoint: Adverse respiratory events. Started Oct 2024; status: completed.
02
Drugs
Sugammadexneostigminerocuronium
03
Conditions
bronchial carcinoma
Beyond the preview
Go deeper on ChiCTR2400094005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400094005.